Tomáš Jelı́nek

13.7k total citations · 1 hit paper
378 papers, 8.9k citations indexed

About

Tomáš Jelı́nek is a scholar working on Public Health, Environmental and Occupational Health, Radiology, Nuclear Medicine and Imaging and Hematology. According to data from OpenAlex, Tomáš Jelı́nek has authored 378 papers receiving a total of 8.9k indexed citations (citations by other indexed papers that have themselves been cited), including 123 papers in Public Health, Environmental and Occupational Health, 98 papers in Radiology, Nuclear Medicine and Imaging and 70 papers in Hematology. Recurrent topics in Tomáš Jelı́nek's work include Boron Compounds in Chemistry (91 papers), Mosquito-borne diseases and control (81 papers) and Malaria Research and Control (73 papers). Tomáš Jelı́nek is often cited by papers focused on Boron Compounds in Chemistry (91 papers), Mosquito-borne diseases and control (81 papers) and Malaria Research and Control (73 papers). Tomáš Jelı́nek collaborates with scholars based in Czechia, Germany and United Kingdom. Tomáš Jelı́nek's co-authors include Michael J. Weber, Thomas W. Sturgill, Paul Dent, Roman Hájek, Bohumil Štı́br, John F. Kennedy, T. Löscher, Alan Wolfman, Jie Wu and J. Plešek and has published in prestigious journals such as Science, New England Journal of Medicine and Journal of the American Chemical Society.

In The Last Decade

Tomáš Jelı́nek

362 papers receiving 8.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Inhibition of the EGF-Activated MAP Kinase Signaling Pathway by Adenosine 3′,5′-Monophosphate

1993 824 citations Tomáš Jelı́nek et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Tomáš Jelı́nek Czechia	46	2.7k	2.4k	1.8k	1.6k	1.1k	378	8.9k
Charles S. Craik United States	76	1.3k 0.5×	10.6k 4.5×	1.2k 0.7×	2.3k 1.4×	98 0.1×	344	19.6k
David Sullivan United States	49	4.0k 1.5×	2.2k 1.0×	123 0.1×	1.3k 0.8×	143 0.1×	255	9.5k
Wesley C. Van Voorhis United States	57	2.8k 1.0×	3.4k 1.4×	444 0.2×	1.5k 0.9×	55 0.1×	274	11.0k
Daniel V. Santi United States	61	1.4k 0.5×	9.9k 4.2×	456 0.3×	1.7k 1.1×	136 0.1×	309	14.6k
Christopher L. King United States	54	3.2k 1.2×	665 0.3×	155 0.1×	1.9k 1.2×	288 0.3×	212	8.3k
Gertrude B. Elion United States	55	1.5k 0.6×	5.4k 2.3×	273 0.2×	2.0k 1.3×	126 0.1×	176	13.0k
Hongmin Li China	48	1.5k 0.6×	2.9k 1.2×	605 0.3×	1.7k 1.0×	72 0.1×	276	8.3k
Pietro Roversi United Kingdom	44	312 0.1×	3.2k 1.3×	488 0.3×	1.3k 0.8×	147 0.1×	125	7.3k
Timothy N. C. Wells Switzerland	74	2.9k 1.0×	5.2k 2.2×	967 0.5×	1.5k 0.9×	47 0.0×	236	19.8k
Daniel E. Goldberg United States	63	7.2k 2.6×	4.2k 1.8×	105 0.1×	1.1k 0.7×	98 0.1×	200	12.4k

Countries citing papers authored by Tomáš Jelı́nek

Since Specialization

Citations

This map shows the geographic impact of Tomáš Jelı́nek's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tomáš Jelı́nek with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tomáš Jelı́nek more than expected).

Fields of papers citing papers by Tomáš Jelı́nek

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tomáš Jelı́nek. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tomáš Jelı́nek. The network helps show where Tomáš Jelı́nek may publish in the future.

Co-authorship network of co-authors of Tomáš Jelı́nek

This figure shows the co-authorship network connecting the top 25 collaborators of Tomáš Jelı́nek. A scholar is included among the top collaborators of Tomáš Jelı́nek based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tomáš Jelı́nek. Tomáš Jelı́nek is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hájek, Roman, et al.. (2025). OMIP‐117: 40‐Parameter/37‐Color Spectral Cytometry Panel for Robust Immunoprofiling of Human Lymphoid Subsets in Cancer Patients. Cytometry Part A. 107(10). 641–648.

Kapoor, Prashant, Nitya Nathwani, Tomáš Jelı́nek, et al.. (2024). An open‐label, first‐in‐human, single agent, dose escalation study for the evaluation of safety and efficacy of SAR442085 in patients with relapsed or refractory multiple myeloma. European Journal Of Haematology. 113(5). 593–605. 1 indexed citations

Simon, Fabrice, Éric Caumes, Tomáš Jelı́nek, et al.. (2023). Chikungunya: risks for travellers. Journal of Travel Medicine. 30(2). 38 indexed citations

Špıčka, Ivan, Maximilian Merz, Jakub Radocha, et al.. (2023). P944: REAL-WORLD PATIENT CHARACTERISTICS AND SURVIVAL OUTCOMES OF LENALIDOMIDE REFRACTORY VS. LENALIDOMIDE EXPOSED RRMM PATIENTS IN THE HONEUR FEDERATED DATA NETWORK. HemaSphere. 7(S3). e258126d–e258126d. 2 indexed citations

Štork, Martin, Ivan Špıčka, Jakub Radocha, et al.. (2023). Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients – real world evidence analysis. Annals of Hematology. 102(6). 1501–1511. 6 indexed citations

Štork, Martin, Sabina Ševčı́ková, Tomáš Jelı́nek, et al.. (2022). Unexpected Heterogeneity of Newly Diagnosed Multiple Myeloma Patients with Plasmacytomas. Biomedicines. 10(10). 2535–2535. 2 indexed citations

Maisnar, Vladimír, Luděk Pour, Ivan Špıčka, et al.. (2022). Patient Characteristics, Treatment Patterns, and Outcomes in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma Patients, a Retrospective Observational Study Using Czech Registry Data. Clinical Lymphoma Myeloma & Leukemia. 23(2). 145–153. 4 indexed citations

Minařík, Jiří, Jakub Radocha, Alexandra Jungová, et al.. (2022). Ixazomib, Lenalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma in Routine Clinical Practice: Extended Follow-Up Analysis and the Results of Subsequent Therapy. Cancers. 14(20). 5165–5165. 5 indexed citations

Gregorová, Jana, Lenka Radová, Lenka Pospíšilová, et al.. (2022). Involvement of Small Non-Coding RNA and Cell Antigens in Pathogenesis of Extramedullary Multiple Myeloma. International Journal of Molecular Sciences. 23(23). 14765–14765. 4 indexed citations

10.

Vdovin, Alexander, Tomáš Jelı́nek, David Žihala, et al.. (2022). The deubiquitinase OTUD1 regulates immunoglobulin production and proteasome inhibitor sensitivity in multiple myeloma. Nature Communications. 13(1). 6820–6820. 16 indexed citations

11.

Hrdinka, Matouš, Ryszard Smolarczyk, Tomasz Cichoń, et al.. (2021). Selection, Expansion, and Unique Pretreatment of Allogeneic Human Natural Killer Cells with Anti-CD38 Monoclonal Antibody for Efficient Multiple Myeloma Treatment. Cells. 10(5). 967–967. 12 indexed citations

12.

Moreno, Laura, Cristina Pérez, Aintzane Zabaleta, et al.. (2019). The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma. Clinical Cancer Research. 25(10). 3176–3187. 148 indexed citations

13.

Jelı́nek, Tomáš, Jana Mihályová, & Roman Hájek. (2018). CD38 targeted treatment for multiple myeloma. Vnitřní lékařství. 64(10). 939–948. 8 indexed citations

14.

Jelı́nek, Tomáš, et al.. (2017). Konsensuspapier Therapie der akuten Reisediarrhö: Eine Praxisempfehlung für die Reiseberatung. MMW - Fortschritte der Medizin. 159. 4–11. 1 indexed citations

15.

Jelı́nek, Tomáš, Aintzane Zabaleta, Cristina Pérez, et al.. (2017). Pre-Clinical Efficacy of the Anti-CD38 Monoclonal Antibody (mAb) Isatuximab in Acute Myeloid Leukemia (AML). Blood. 130. 2655–2655. 3 indexed citations

16.

Ševčíková, Tereza, Kateřina Growková, Tomáš Jelı́nek, et al.. (2017). Biobanking strategy and sample preprocessing for integrative research in monoclonal gammopathies. Journal of Clinical Pathology. 70(10). 847–853. 4 indexed citations

17.

Burchard, Gerd, Éric Caumes, Bradley A. Connor, et al.. (2009). Expert Opinion on Vaccination of Travelers Against Japanese Encephalitis. Journal of Travel Medicine. 16(3). 204–216. 42 indexed citations

18.

Heidari, Aliehsan, Hossein Keshavarz, Sabine Dittrich, & Tomáš Jelı́nek. (2009). Allelic Dimorphism of the Plasmodium falciparum Erythrocyte Binding Antigen-175 (EBA-175) Gene in the Southeast of Iran. SHILAP Revista de lepidopterología. 3 indexed citations

19.

Jelı́nek, Tomáš & Hans Dieter Nothdurft. (2006). Changing Epidemiology of Hepatitis A: Time for Vaccination in Childhood. Journal of Travel Medicine. 7(3). 142–148. 3 indexed citations

20.

Günther, Matthias, et al.. (2003). Akute virale Gastroenteritis. Zeitschrift für Allgemeinmedizin. 79(8). 380–383. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact